Contineum Therapeutics, Inc. 8-K

What Happened

• On April 30, 2026, Contineum Therapeutics announced topline results from its exploratory PIPE-791 Phase 1b randomized, double-blind, placebo-controlled, 4-week crossover trial in chronic pain (ClinicalTrials.gov NCT06810245). The trial enrolled 43 patients (23 with chronic osteoarthritic pain, COAP; 20 with chronic low back pain, CLBP). The study met its primary safety/tolerability objective: most treatment-emergent adverse events (TEAEs) were mild-to-moderate, there were no serious AEs, and no clinically meaningful changes in blood pressure or orthostatic events were observed.

Key Details

• Trial design & enrollment: 43 patients total (COAP n=23; CLBP n=20); randomized, double-blind, placebo-controlled, 4-week crossover.
• Safety: AE profile consistent with prior PIPE-791 trials; most common TEAEs were headache (n=3) and fatigue (n=2); no serious adverse events reported.
• Exploratory efficacy (PI-NRS pain scores): Patients on PIPE-791 showed numerically greater improvements versus placebo. Example (Treatment Period 1 weekly average of daily PI-NRS):
  • COAP PIPE-791 (N=11): baseline 5.58 (SD 1.21); change from baseline −1.60 (95% CI −2.49, −0.72) vs placebo −1.27 (95% CI −2.15, −0.39).
  • CLBP PIPE-791 (N=10): baseline 5.60 (SD 1.27); change −1.33 (95% CI −1.83, −0.84) vs placebo −0.55 (95% CI −1.33, 0.22).
• Additional exploratory measures (30% responder rate and Modified KOOS) supported the PI-NRS findings.

Why It Matters

• For investors, the filing shows PIPE-791 was generally well tolerated in this small Phase 1b study and produced exploratory signals of pain reduction versus placebo. These results are early and exploratory (small sample size, short duration, crossover design) and are intended to inform further development rather than demonstrate definitive efficacy.
• The company highlights forward-looking risks: PIPE-791 and PIPE-307 remain early-stage programs, and future clinical or regulatory outcomes are uncertain. Investors should treat these topline results as encouraging preliminary data but not proof of clinical or commercial success.